Skip to main content
Premium Trial:

Request an Annual Quote

U. of Dundee Gets 15 Million in Renewal of Proteomics Collaboration with Pharma

MNEW YORK, March 18 - The University of Dundee said today it had renewed a proteomics research collaboration with big pharma that will net it £15 million ($23.4 million) over five years-the largest research funding award ever for the Scottish academic center.

 

The Universityof DundeeSchool of Life Sciences and the UK's Medical Research Council will work with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, and Pfizer to study kinases and phosphatases in order to better understand these groups of proteins as drug targets for major diseases, a university statement said.

 

The funding nearly doubles the amount that the school was awarded for the previous five years of this project.

 

The project research will take place at the division of signal transduction therapy, based at the Wellcome Trust Biocenter, which is co-directed by Sir Philip Cohen, director of the Medical Research Council protein phosphorylation unit, and professor Peter Downes of the MRC inositol phospholipid signalling laboratory. Eleven other research groups in the MRC protein phosphorylation unit will also participate in the research, the university said.